Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783588 | 0.88 | CES2 (0.39) | SLC6A2CES2CES1CYP3A4ADRB1 | |
| SCHEMBL3146619 | 0.88 | CES2 (0.39) | SLC6A2CES2CES1CYP3A4ADRB1 | |
| SCHEMBL20943373 | 0.87 | PSEN1 (0.34) | CES2CES1TRPM8GMNNTP53 | |
| SCHEMBL20943374 | 0.87 | PSEN1 (0.34) | CES2CES1TRPM8GMNNTP53 | |
| SCHEMBL20868369 | 0.81 | LMNA (0.42) | CES2CES1TRPM8ADRB1METAP2 | |
| SCHEMBL30512207 | 0.81 | LMNA (0.42) | CES2CES1TRPM8ADRB1METAP2 | |
| SCHEMBL24726411 | 0.80 | CES2 (0.31) | CES2CES1 | |
| SCHEMBL25831631 | 0.75 | AOC3 (0.41) | SLC6A2TRPM8CYP3A4ADRB1LMNA | |
| SCHEMBL25304349 | 0.75 | AOC3 (0.41) | SLC6A2TRPM8CYP3A4ADRB1LMNA | |
| SCHEMBL3138467 | 0.74 | CES2 (0.45) | SLC6A2CES2CES1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687529-B2 | Substituted propylamine derivatives and methods of their use | WYETH LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7601744-B2 | Benzothiadiazolylphenylalkylamine derivatives and methods of their use | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1934193-A1 | BENZOTHIADIAZOLYPHENYLALKYLAMINE DERIVATIVES FOR USE IN THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE | Wyeth a Corporation of the State of Delaware (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1934178-A2 | SUBSTITUTED PROPYLAMINE DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007041258-A1 | BENZOTHIADIAZOLYPHENYLALKYLAMINE DERIVATIVES FOR USE IN THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041257-A2 | SUBSTITUTED PROPYLAMINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072928-A1 | treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; 1'-[3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1'H)-one | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072918-A1 | Benzothiadiazolylphenylalkylamine derivatives and methods of their use | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072928-A1 | treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; 1'-[3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1'H)-one | TPH1, HTR1A, HTR5A | SLC6A2 9/4885CES2 1554/4885CES1 909/4885 |
| US-20070072918-A1 | Benzothiadiazolylphenylalkylamine derivatives and methods of their use | GLS, SLC6A4, SLC6A3 | SLC6A2 11/4885CES2 606/4885CES1 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.